GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a multigenic investigational therapeutic candidate under evaluation for the treatment of heart failure, the leading cause of death worldwide. The Phase 1 open label study is designed to investigate the safety of INXN-4001 delivered via Retrograde Coronary Sinus Infusion (RCSI) in patients with an implanted Left Ventricular Assist Device (LVAD) for mechanical support of end-stage heart failure, either as a bridge to transplant or destination therapy (clinical trial identifier: NCT03409627).
"We are excited to have reached this important milestone in the clinical evaluation of INXN-4001 for treatment of end-stage heart failure," stated Amit Patel, MD, MS, Co-Founder and Medical Director of TripleGene. "Heart failure rarely results from a single genetic defect, and while single gene therapy approaches have been studied, these treatments may not fully address the causes of the disease. Our unique multigenic approach is designed to stimulate biological activity targeting multiple points in the disease progression pathway."
Triple-Gene's investigational therapy uses non-viral delivery of a constitutively expressed multigenic plasmid designed to express human S100A1, SDF-1, and VEGF165 gene products, which affect progenitor cell recruitment, angiogenesis, and calcium handling, respectively, and target the underlying molecular mechanisms of pathological myocardial remodeling. The plasmid therapy is delivered via RCSI which allows for cardiac-specific delivery to the ventricle.
"Heart failure is the leading cause of death worldwide and represents a significant and growing global health problem. Aside from heart transplant and LVAD, current treatment options for those patients with end-stage disease are limited," commented Timothy Henry, MD, FACC, MSCAI, Medical Director of the Carl and Edyth Lindner Center for Research and Education at The Christ Hospital and a member of the Triple-Gene Medical Advisory Board. "The INXN4001 investigational therapy represents a biologically-based method focused on repairing the multiple malfunctions of cardiomyocytes, and I look forward to seeing the results of this initial safety study and further exploring the promise of this innovative treatment approach."
Triple-Gene will present preliminary data from the Phase 1 study at the American Heart Association Scientific Sessionsat the Pennsylvania Convention Center in Philadelphia. A poster titled "Safety of First in Human Triple-Gene Therapy Candidate for Heart Failure Patients" will be presented on Sunday, November 17th from 3:00 pm - 3:30 pm ETin Zone 4 of the Science and Technology Hall.
About the Phase 1 Trial of INXN-4001INXN-4001 is being evaluated in a Phase I open label study in adult patients with implanted Left Ventricular Assist Device (LVAD). The study is designed to investigate the safety and feasibility of supplemental cardiac expression of S100A1, SDF-1 and VEGF-165 from a single, multigenic plasmid delivered via Retrograde Coronary Sinus Infusion (RCSI) in stable patients implanted with a LVAD for mechanical support of end-stage heart failure. Twelve stable patients with an implanted LVAD were allocated into 2 cohorts (6 subjects each) to evaluate the safety and feasibility of infusing 80mg of INXN4001 in either a 40mL (Cohort 1) or 80mL (Cohort 2) volume. The primary endpoint of safety and feasibility is assessed at the 6-month endpoint. Daily activity data are also collected throughout the study using a wearable biosensor. Dosing on both Cohorts 1 and 2 has been completed, and patients continue follow-up per protocol.
About Triple-GeneTriple-Gene LLC is a clinical stage gene therapy company focused on advancing targeted, controllable, and multigenic gene therapies for the treatment of complex cardiovascular diseases. The Company's lead product is a non-viral investigational gene therapy candidate that drives expression of three candidate effector genes involved in heart failure. Triple-Gene is a majority owned subsidiary of Intrexon Corporation(NASDAQ: XON) co-founded by Amit Patel, MD, MS, and Thomas D. Reed, PhD, Founder and Chief Science Officer of Intrexon. Learn more about Triple-Gene at http://www.3GTx.com.
About Intrexon CorporationIntrexon Corporation (NASDAQ: XON) is Powering the Bioindustrial Revolution with Better DNAto create biologically-based products that improve the quality of life and the health of the planet through two operating units Intrexon Health and Intrexon Bioengineering. Intrexon Health is focused on addressing unmet medical needs through a diverse spectrum of therapeutic modalities, including gene and cell therapies, microbial bioproduction, and regenerative medicine. Intrexon Bioengineering seeks to address global challenges across food, agriculture, environmental, energy, and industrial fields by advancing biologically engineered solutions to improve sustainability and efficiency. Our integrated technology suite provides industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA, and we invite you to discover more at http://www.dna.comor follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.
TrademarksIntrexon, Powering the Bioindustrial Revolution with Better DNA,and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners.
Safe Harbor Statement Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.
For more information contact:
Investor Contact:
Steven Harasym
Vice President, Investor Relations
Intrexon Corporation
Tel: +1 (301) 556-9850
Corporate Contact:
Marie Rossi, PhD
Vice President, Communications
Intrexon Corporation
Tel: +1 (301) 556-9850
Read the original post:
- Managing Right Ventricular Failure in PAH: An Algorithmic Approach | Advances in ... - April 13th, 2018 [April 13th, 2018]
- What Is the Ejection Fraction? - Verywell Health - May 12th, 2018 [May 12th, 2018]
- Ventricular septal defect - Wikipedia - June 21st, 2018 [June 21st, 2018]
- Heart Failure Medication: Beta-Blockers, Alpha Activity ... - July 7th, 2018 [July 7th, 2018]
- Acute Management of Pulmonary Embolism - American College ... - July 17th, 2018 [July 17th, 2018]
- Ventricular Remodeling | Profiles RNS - July 24th, 2018 [July 24th, 2018]
- Left ventricular hypertrophy - Wikipedia - August 20th, 2018 [August 20th, 2018]
- Ventricular Remodeling Surgery (SVR) - September 24th, 2018 [September 24th, 2018]
- Left Ventricular Remodeling in Heart Failure | JACC ... - November 25th, 2018 [November 25th, 2018]
- Ventricular dysfunction in heart failure - Britannica.com - December 25th, 2018 [December 25th, 2018]
- TIMI Study Group - LEADERSHIP - January 31st, 2019 [January 31st, 2019]
- Ventricular Remodeling Procedure | Main Line Health ... - February 24th, 2019 [February 24th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Coherus BioSciences Inc. (NASDAQ:CHRS) - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Reviewing Aeterna Zentaris Inc. (AEZS)'s and BioLineRx Ltd. (NASDAQ:BLRX)'s results - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Karuna Therapeutics Inc. (KRTX) and BioLineRx Ltd. (NASDAQ:BLRX) Comparing side by side - Stocks Beat - September 18th, 2019 [September 18th, 2019]
- Arbutus Biopharma Corporation (ABUS)'s Financial Results Comparing With BioLineRx Ltd. (NASDAQ:BLRX) - The EN Herald - September 18th, 2019 [September 18th, 2019]
- Cardiac Dimensions touts Carillon TMVR study - Mass Device - September 18th, 2019 [September 18th, 2019]
- New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF - TCTMD - September 18th, 2019 [September 18th, 2019]
- Cardiac Restoration Systems Market Will Make a Huge Impact in Near Future - Wolf Mirror - September 18th, 2019 [September 18th, 2019]
- Reduce Fmr Study Shows Cardiac Dimensions' Carillon System Significantly Improves Mitral Regurgitation And Slows Worsening Of Heart Failure - TCTMD - September 18th, 2019 [September 18th, 2019]
- Heart Failure Society of America 2019: Virtual Visits, Spironolactone Issues, and Reasons to Worry - DocWire News - September 18th, 2019 [September 18th, 2019]
- LV Reverse Remodeling Not Improved by SGLT-2 Inhibitor - DocWire News - September 18th, 2019 [September 18th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Soligenix Inc. (NASDAQ:SNGX) - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Biolinerx LTD. American Depositary Shares (NASDAQ:BLRX) Could Burn Your Long Portfolio After More Shorts - The MAK Daily - September 22nd, 2019 [September 22nd, 2019]
- Reviewing BioLineRx Ltd. (BLRX)'s and Dicerna Pharmaceuticals Inc. (NASDAQ:DRNA)'s results - CryptoCoinsTribune - September 22nd, 2019 [September 22nd, 2019]
- Comparison of Protalix BioTherapeutics Inc. (PLX) and BioLineRx Ltd. (NASDAQ:BLRX) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Edge Therapeutics Inc. (:) - MS Wkly - October 19th, 2019 [October 19th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Protalix BioTherapeutics Inc. (NYSEAMERICAN:PLX) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- BioLineRx Ltd. (BLRX)'s Financial Results Comparing With Cyanotech Corporation (NASDAQ:CYAN) - The Broch Herald - November 7th, 2019 [November 7th, 2019]
- Contrasting of BioLineRx Ltd. (BLRX) and Moderna Inc. (NASDAQ:MRNA) - The Broch Herald - December 3rd, 2019 [December 3rd, 2019]
- Edited Transcript of MYOK earnings conference call or presentation 11-Nov-19 1:30pm GMT - Yahoo Finance - December 3rd, 2019 [December 3rd, 2019]
- Cardiac Restoration Systems Market: Key Growth Factors and Industry Analysis 2018 - 2028 - The Market Expedition - December 3rd, 2019 [December 3rd, 2019]
- Velocity Transfer Function In The Right Pulmonary Artery And Impaired | COPD - Dove Medical Press - December 3rd, 2019 [December 3rd, 2019]
- 3 Stocks to Buy Ahead of the Next Market Crash - The Motley Fool - December 3rd, 2019 [December 3rd, 2019]
- Pulmonary Hypertension, Common in TAVR Patients, Linked to Lower Survival - TCTMD - December 3rd, 2019 [December 3rd, 2019]
- Patients With Chemotherapy-Induced Cardiomyopathy Show Improvements in LVEF After Cardiac Resynchronization Therapy - AJMC.com Managed Markets Network - December 4th, 2019 [December 4th, 2019]
- BioVentrix Announces Publication of Positive One-Year Outcomes for Revivent TC System - Yahoo Finance - December 4th, 2019 [December 4th, 2019]
- Cardiac Restoration Systems Market Forecasted To Surpass The Value Of US$ XX Mn/Bn By 2055 2017 2025 - Weekly News Times - December 13th, 2019 [December 13th, 2019]
- The Outer Line: The impact of endurance training on the cardiac health of women - VeloNews - December 13th, 2019 [December 13th, 2019]
- Contrasting of Insmed Incorporated (INSM) and BioLineRx Ltd. (NASDAQ:BLRX) - The CoinGlobalist - December 16th, 2019 [December 16th, 2019]
- CARDIAC RESTORATION SYSTEMS MARKET ANALYSIS TRENDS, GROWTH OPPORTUNITIES, SIZE, TYPE, DYNAMIC DEMAND AND DRIVES WITH FORECASTS TO 2028 - Voice of... - January 13th, 2020 [January 13th, 2020]
- Early Expressed Circulating Long Noncoding RNA CHAST is Associated with Cardiac Contractile Function in Patients with Acute Myocardial Infarction -... - January 13th, 2020 [January 13th, 2020]
- Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone - DocWire News - January 23rd, 2020 [January 23rd, 2020]
- Increased Long-Term Risk for Venous Thromboembolism After Heart Failure - The Cardiology Advisor - January 23rd, 2020 [January 23rd, 2020]
- Retinoid X receptor alpha is a spatiotemporally predominant therapeutic target for anthracycline-induced cardiotoxicity - Science Advances - February 1st, 2020 [February 1st, 2020]
- Coronary Microvascular Dysfunction Found to Increase Risk for CV Events in Chronic Kidney Disease - The Cardiology Advisor - February 1st, 2020 [February 1st, 2020]
- New Data Confirms Cardiac Dimensions' Carillon System Shows Favorable Long-Term Survival Rate In Patients With Functional Mitral Regurgitation -... - February 26th, 2020 [February 26th, 2020]
- BioVentrix Announces Ralph Stephan von Bardeleben, MD, as Co- Principal Investigator of the REVIVE-HF Clinical Trial - Yahoo Finance - March 5th, 2020 [March 5th, 2020]
- Relationship between histopathological features of aspirated thrombi and long-term left ventricular function in patients with ST-segment elevation... - March 15th, 2020 [March 15th, 2020]
- FierceMedTech Names BioVentrix as One of Its "Fierce 15" Companies of 2019 - Yahoo Finance - March 15th, 2020 [March 15th, 2020]
- Causes and Prevention of Ventricular Remodeling After MI ... - March 16th, 2020 [March 16th, 2020]
- Left Ventricular Remodelling - ECR Journal - April 23rd, 2020 [April 23rd, 2020]
- Cardiac Restoration Systems Market to Make Great Impact in Near Future by 2026 - The Canton Independent Sentinel - June 12th, 2020 [June 12th, 2020]
- Multi-Society Guidelines on the Use of Multimodality CV Imaging in Competitive Athletes - The Cardiology Advisor - June 12th, 2020 [June 12th, 2020]
- Chronic PDE5i Treatment Found to Improve Cardiac Remodeling in Men, but Not Women, With Diabetic Cardiomyopathy - Endocrinology Advisor - June 12th, 2020 [June 12th, 2020]
- Acceleron to Host Conference Call and Webcast to Review Results of PULSAR Phase 2 Trial of Sotatercept Presented at American Thoracic Society 2020... - June 23rd, 2020 [June 23rd, 2020]
- American Heart Association and Barth Syndrome Foundation Partner to Address Rare Disease - PR Web - August 29th, 2020 [August 29th, 2020]
- The Association of Cardio-Ankle Vascular Index (CAVI) with Biatrial Remodeling in Atrial Fibrillation - DocWire News - September 3rd, 2020 [September 3rd, 2020]
- Cardiac Dimensions Announces Australian Therapeutic Goods Administration's Approval of the Carillon System for the Treatment of Functional Mitral... - September 3rd, 2020 [September 3rd, 2020]
- Sep 4 2020 This Week in Cardiology - Medscape - September 5th, 2020 [September 5th, 2020]
- Emerging treatment helps reverse heart failure in some patients - Science Codex - October 27th, 2020 [October 27th, 2020]
- GMAX Biopharm gives first does of anti-body drug treating PAH in phase 1B trial - PRNewswire - October 27th, 2020 [October 27th, 2020]
- North America to Outshine the Global Slowdown in Cardiac Restoration Systems market between 2020 and 2030 - The Think Curiouser - November 12th, 2020 [November 12th, 2020]
- Age-Related Development of Cardiac Remodeling and Dysfunction in Young Black and White Adults: the Coronary Artery Risk Development in Young Adults... - November 25th, 2020 [November 25th, 2020]
- Adiponectin receptor 1 variants contribute to hypertrophic cardiomyopathy that can be reversed by rapamycin - Science Advances - January 13th, 2021 [January 13th, 2021]
- Longer Survival Seen in Heart Failure Stabilized Via Cardiac Resynchronization Therapy - The Cardiology Advisor - April 13th, 2021 [April 13th, 2021]
- Cardiac Dimensions Welcomes Robert White to its Board of Directors - PRNewswire - April 13th, 2021 [April 13th, 2021]
- [Full text] SIRT1 is Required for Exercise-Induced Beneficial Effects on Myocardia | JIR - Dove Medical Press - April 13th, 2021 [April 13th, 2021]
- Role of Pyroptosis in Diabetes and Its Therapeutic Implications | JIR - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Epigenetic therapies for heart failure | VHRM - Dove Medical Press - May 25th, 2021 [May 25th, 2021]
- Are you at risk for sudden death, and can it be prevented? - Jamaica Observer - May 25th, 2021 [May 25th, 2021]
- Does a plant-based diet improve cardiac function? Here's the answer - Hindustan Times - June 21st, 2021 [June 21st, 2021]
- Early Use of Sacubitril/Valsartan Linked to Improved Cardiac Function Post AMI - AJMC.com Managed Markets Network - November 5th, 2021 [November 5th, 2021]
- Higher BP, LV Changes Seen in Children Conceived by ART - Medscape - November 5th, 2021 [November 5th, 2021]
- Regional Heterogeneity in Determinants of Atrial Matrix Remodeling and Association with Atrial Fibrillation Vulnerability Post-Myocardial Infarction -... - January 26th, 2022 [January 26th, 2022]
- 4 promising heart failure therapies interventional cardiologists should keep an eye on - Cardiovascular Business - May 7th, 2022 [May 7th, 2022]
- LEXEO Therapeutics Announces Data Presentations at the 25th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting - Yahoo Finance - May 7th, 2022 [May 7th, 2022]
- Ventricular structure and function in hypertensive patients | IJGM - Dove Medical Press - May 7th, 2022 [May 7th, 2022]
- Effects of diabetes mellitus on left ventricular function and remodeling in hypertensive patients with heart failure with reduced ejection fraction:... - May 7th, 2022 [May 7th, 2022]
- Cardior Announces CE Marking of CardiorHealth miR-132 PCR Kit Used in Ongoing HF-REVERT Phase 2 Clinical Study - Business Wire - September 12th, 2022 [September 12th, 2022]